Hydroxyurea
  action of, 103e-4, 103e-10t, 103e-14, 632
  adverse effects of, 103e-10t, 379, 649
  for chronic myelomonocytic leukemia, 135e-6
  for CML, 694
  for hypereosinophilic syndromes, 423
  for sickle cell anemia, 636
Hydroxyzine
  for angioedema, 2119
  for ciguatera poisoning, 2742
  for pruritus, 345
  for urticaria, 2119
Hygiene hypothesis, 1670
Hymen, imperforate, 335
Hymenolepiasis diminuta, 1434
Hymenolepiasis nana (dwarf tapeworm), 245e-2t, 246e-11, 765t, 1434
Hymenoptera venom/sting, 2116, 2748–2749
Hyoscyamine, 473e-8t, 2672
Hypalgesia, 158
Hyperabduction maneuver, 1647
Hyperacute rejection, 1827
Hyperaldosteronism
  diagnosis of, 307, 1618–1619
  familial type I. *See* Glucocorticoid-remediable aldosteronism (GRA)
  familial types II and III, 306
  genetic considerations in, 306, 307
  hyperreninemic, secondary, 321–322
  hypertension in, 1614, 1618
  hypokalemia in, 306
  idiopathic, 306
  metabolic acidosis in, 320–321
  mineralocorticoid excess in. *See* Mineralocorticoid excess
  primary, 306, 307, 1614, 1618–1619
  secondary, 306, 1614
  treatment of, 1619
  weakness in, 462e-119
Hyperalgesia, 87, 158
Hyperammonemia, 434e-3t, 434e-5, 435e-1t, 435e-2, 1996
Hyperamylasemia, 2089t
Hyperamylasuria, 2089t
Hyperbaric medicine, 477e-1, 477e-1f
Hyperbaric oxygen therapy, **477e-1**
  for acute coronary syndrome, 477e-4t
  adverse effects of, 477e-2
  for altitude illness, 476e-2t, 476e-3, 476e-4
  for carbon monoxide poisoning, 477e-5–6
  for chronic wounds, 477e-3, 477e-4t, 477e-5, 477e-5f
  contraindications to, 477e-2
  for decompression sickness, 477e-4t, 477e-8
  for gas gangrene, 833, 994
  for idiopathic sudden sensorineural hearing loss, 477e-4t
  indications for, 477e-3, 477e-3t
  for late radiation tissue injury, 477e-3, 477e-4t
  mechanisms of, 477e-1, 477e-2f
  for radiation therapy enhancement, 477e-4t
  for soft tissue infections, 1102
  for traumatic brain injury, 477e-4t
Hyperbilirubinemia, **2000**
  in alcoholic liver disease, 2053, 2053t
  approach to the patient, 281–282, 281f
  conjugated
    in benign recurrent intrahepatic cholestasis, 284, 2003t, 2004
    differential diagnosis of, 282
    in Dubin-Johnson syndrome, 282, 2003–2004, 2003t
    with other liver abnormalities
      approach to the patient, 281f, 282–283
      in cholestatic disorders, 283–285, 284t
      in hepatocellular disease, 283, 283t
    in progressive familial intrahepatic cholestasis, 284, 2003t, 2004
    in Rotor syndrome, 282, 2003t, 2004
    in sepsis/septic shock, 1756
  isolated, 281–282, 282t
  in pancreatitis, 2093
  pathophysiology of, 280
  unconjugated
    from decreased hepatic bilirubin clearance, 2001
    differential diagnosis of, 281–282, 282t
    from hereditary defects. *See* Crigler-Najjar syndrome; Gilbert's syndrome
    from increased bilirubin production, 2000
Hypercalcemia, **313**, **2469**
  in adult T-cell leukemia/lymphoma, 225e-4
  after kidney transplantation, 1831
  aluminum intoxication and, 2479
  asymptomatic, 2479
  bone turnover–associated, 2478
  chronic, 1862, 2479, 2479f
  in chronic kidney disease, 1815, 2478
  clinical features of, 96e-9t, 152, 313, 463e-4, 2469–2470
  diagnosis of, 314, 2469–2470, 2479fl
  differential diagnosis of, 2469–2470, 2479–2480, 2479fl
  ECG in, 269e-13f, 269e-14f, 1457, 1458f
  etiology of, 313, 313t, 2469, 2470t, 2480
  familial hypocalciuric. *See* Familial hypocalciuric hypercalcemia (FHH)
  genetic considerations in, 2475, 2476f
  in hyperparathyroidism. *See* Hyperparathyroidism, primary
  hypertension in, 1620
  hyperthyroidism and, 2478
  idiopathic, of infancy, 83e-6, 2477–2478
  immobilization and, 2478
  inpatient neurologic consultation for, 463e-4
  lithium therapy and, 2475
  malignancy-associated, **609**
    clinical features of, 610, 2479–2480
    clinical syndromes related to, 2475–2477
    diagnosis of, 610, 2476–2477
    etiology of, 609–610, 609t
    mechanisms of, 2476
    pathogenesis of, 609t
    treatment of, 610, 2477
  in metastatic bone disease, 119e-4
  in milk-alkali syndrome, 313, 2458, 2479
  in multiple myeloma, 714, 717
  in nephrogenic diabetes insipidus, 303
  in Paget's disease of bone, 426e-3
  with parenteral nutrition, 98e-7t
  pNET and, 559t, 571
  renal effects of, 1862
  in sarcoidosis, 2208, 2477
  thiazides and, 2478
  treatment of, 314, 610, 2480–2482, 2480t
  vitamin A intoxication and, 2478
  vitamin D–related, 2477–2478
Hypercalciuria
  in Bartter's syndrome, 306, 2483
  hematuria and, 294
  hypocalcemic, 2483
  loop diuretics and, 306
  nephrolithiasis risk and, 1867
  in Paget's disease of bone, 426e-3
Hypercapnia, 315
  metabolic alkalosis following, 322
  permissive, 322, 1741
  in respiratory acidosis, 323
Hypercholesterolemia. *See also* Lipoprotein disorders
  autosomal dominant type 2, 2442
  autosomal dominant type 3, 2442
  autosomal recessive, 2442
  familial, 436e-4f, 2440t, 2441–2442, 2449
  severe, 2446
Hypercortisolism, 2271. *See also* Cushing's syndrome
HyperC-VAD regimen, 704
Hyperemesis gravidarum, 49, 259, 2300
Hypereosinophilic syndromes (HES)
  clinical features of, 135e-8, 1567, 1686, 2683
  diagnosis of, 135e-8, 135e-t
  diseases associated with, 422
  idiopathic, 422–423
  pathophysiology of, 372e-8, 1567
  subtypes of, 135e-7, 135e-7t, 1686
  treatment of, 135e-8, 1686
Hyperesthesia, 158
Hyperfiltration, glomerular, 333e-1
Hyperfiltration hypothesis, 333e-1
Hypergammaglobulinemia, 2050
Hypergastrinemia, 568, 1927
Hyperglobulinemia, 64e-6
Hyperglycemia
  β-agonists and, 312
  in cardiogenic shock, 1760
  clinical features of, 2406
  in diabetic ketoacidosis. *See* Diabetic ketoacidosis (DKA)
  hypernatremia in, 303
  hyponatremia in, 301
  in overdosage/poisoning, 473e-3
  in pancreatitis, 2092–2093
  with parenteral nutrition, 98e-7
  perioperative, 55
  in sepsis/septic shock, 1756
  with specialized nutritional support, 98e-4
  in systemic inflammatory response syndrome, 98e-4
Hyperglycemic hyperosmolar state (HHS), 2417t, 2420
Hypergonadotropic hypogonadism, 336–337
Hyperhidrosis, primary, 2643
Hyperhomocysteinemia
  cardiac manifestations of, 290e-1t, 290e-2
  clinical features of, 434e-4
  pyridoxine deficiency in, 96e-4
  risk factors for, 434e-4
  treatment of, 434e-4
  venous thrombosis risk in, 744
Hyperhomocystinurias, 434e-1, 434e-4
Hyperhydroxyprolinemia, 434e-2t
Hyper-IgD syndrome, 126
Hyper-IgE syndrome (Job's syndrome), **423**
  autosomal dominant, 375e-2, 2109
  autosomal recessive, 2109
  cellular/molecular defects in, 420t, 423
  clinical features of, 375e-2, 420t, 423, 830, 2109
  diagnosis of, 420t, 2109
  monocytosis in, 421
Hyper-IgM syndrome, 2110, 2110f, 2111
Hyperimmune equine immunoglobulin, 1328
Hyperimmunoglobulinemia D with periodic fever syndrome (HIDS), 2213t, 2215
Hyperinflation, 47e-1, 1702
Hyperinsulinemia, 98e-7, 332, 2405
Hyperinsulinism, endogenous, 2434
Hyperkalemia, **308**
  in acute kidney injury, 1808
  after adrenalectomy, 1619
  AV conduction block in, 1471t
  in chronic kidney disease, 333e-2, 1814, 1815
  clinical features of, 310–311
  definition of, 308
  diagnosis of, 311, 311f
  drug-induced, 43, 64e-2, 310
  ECG in, 310, 1457, 1458f
  etiology of, 304, 308–310, 309t
  in HIV infection, 310
  inpatient neurologic consultation for, 463e-4
  metabolic acidosis in, 64e-2–3
  in overdosage/poisoning, 473e-3
  with parenteral nutrition, 98e-7t
  rebound, 307
  renal effects of, 1862
  transfusion-related, 138e-5
  treatment of, 64e-3, 312, 463e-4
  in tumor lysis syndrome, 1795
  urinary tract obstruction and, 1872
  ventricular tachycardia in, 1489
Hyperkalemic periodic paralysis (HyperKPP)
  channelopathies in, 444e-2t
  clinical features of, 310, 462e-3, 462e-17–18, 462e-17t
  diagnosis of, 462e-18
  early interventions for, 450t
  genetic considerations in, 444e-2t, 462e-17f, 462e-18